{Reference Type}: Journal Article
{Title}: Association between anti-SSA autoantibodies and conduction disturbances in heart failure.
{Author}: Hua C;Jiang C;Wang Z;Liu X;Fu H;Lin J;Lv Q;Dong J;Ma C;Du X;
{Journal}: Heart Rhythm
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 5
{Factor}: 6.779
{DOI}: 10.1016/j.hrthm.2024.05.060
{Abstract}: <B>BACKGROUND: </B>Conduction disturbances play an important role in the occurrence and development of heart failure (HF). Studies suggest autoantibodies may attack the conduction system. However, whether autoantibodies are associated with conduction disturbances in patients with HF is unclear.<BR><B>OBJECTIVE: </B>The purpose of this study was to assess whether anti-SSA, anti-Ro/Sjögren syndrome-related antigen A antibodies known for congenital atrioventricular block (AVB), is associated with conduction disturbances in patients with HF.<BR><B>METHODS: </B>This retrospective observational study used data from patients with HF who were admitted to Beijing Anzhen Hospital between January 2018 and June 2022. Patients who were tested for anti-SSA and had undergone electrocardiographic examination during hospitalization were included. Conduction disturbances, including AVB, bundle branch block (BBB), and intraventricular conduction delay, were confirmed by a cardiologist blinded to anti-SSA status. Univariate and multivariable logistic regression analyses were performed to assess the association between anti-SSA and conduction disturbances.<BR><B>RESULTS: </B>A total of 766 patients were included in this study, of whom 70 (9.1%) were anti-SSA positive. Subjects who were anti-SSA positive showed a higher prevalence of AVB (20% vs 10.6%) and BBB (27.3 % vs 10.9 %), including both left BBB and right BBB (all P <.05). After adjusting for known risk factors, anti-SSA was independently associated with AVB (odds ratio [OR] 2.42; 95% confidence interval [CI] 1.18-5.43; P = .03) and BBB (OR 3.15; 95% CI 1.68-5.89; P <.001).<BR><B>CONCLUSIONS: </B>Anti-SSA is independently associated with AVB and BBB in patients with HF. Further study of the role of autoantibodies in the development of conduction abnormalities in patients with HF to generate possible targeted treatments is required.